ADHC One crazy play here!! DD inside **MUST READ**

I found a very interesting play thats been catching a lot attention and momentum lately. ADHC put out news today about a major acquisition thats a lot bigger than most acquisitions I’ve seen in the OTC. It’s a pennystock however, it trades like a smallcap nasdaq with a nasdaq quality team.

Based on todays news ADHC is acquiring GlucoGuard which is a AI medical device for Diabetes. The company developing the medical device is Dexcom DXCM which is a giant $27B MC company trades at $68 per share so it looks like the real deal. What makes it even more interesting is the team behind the company which includes Bill Colone.

Bill Colone has a pretty insane track record in the bio device field and still very active. He’s the current CEO of SinglePass which recently got FDA clearance in April for their Kronos biopsy closure device.

Bill Colone also sold his first startup Endomed to LeMaitre Vascular LMAT, a giant $2B MC company.

In addition to that, Bill Colone helped position a surgical vascular graft product company IMPRA Inc which later was acquired by CR Bard for $143M. Bill was Director of Operations of IMPRA for 11 years.

Now Bill Colone is working with ADHC a tiny little pennystock with a market cap of $3.7M. He recently joined ADHC advisory board on June of this year.

Today, ADHC released news that they’re acquiring GlucoGuard. Bill Colone added, "Hypoglycemia, particularly during sleep, is a persistent and dangerous issue for diabetic patients, often leading to serious consequences like the dreaded 'Death in Bed' syndrome. GlucoGuard's technology offers a game-changing solution to this pressing problem."

“In addition to the acquisition, GlucoGuard's founder, Zachary Smith, BS/MS Biomedical Engineering (Arizona State University), will join ADHC's advisory board. Smith will work alongside Bill Colone, a renowned expert in biomedical solutions, to advance GlucoGuard's development and integration into ADHC's expanding healthcare technology portfolio.”

ADHC also had other positive news recently.
On August 26 the company announced that they negotiated the elimination of $2.7M in debt from their balance sheet, creating a DEBT-FREE company.

Also on August 29 ADHC announced cancellation of 142 million shares bringing the total cancellation of shares to 466 million shares.

Aside from that, the stock chart looks absolutely amazing, seriously. The stock is very liquid and trades on high volume daily.

Now going back to the acquisition which is actually very interesting and the biggest catalyst of them all.

The GlucoGuard device is a pain-free and non invasive way to detect blood sugar levels and deliver glucose when needed.
It's the ONLY device to treat nocturnal hypoglycemia. For people that suffer from Diabetes, there is the constant issue of monitoring blood sugar levels. While low blood sugar can happen at any time during the day, many people may experience low blood sugar while they sleep. This known as "Nocturnal Hypoglycemia"

GlucoGuard is an oral retainer worn while sleeping and is the only medical device designed to automatically deliver glucose when needed and reduce the risks associated with hypoglycemia.

Also worth mentioning the target market is absolutely huge for this device. It is estimated that 422 million people are living with Diabetes worldwide.

Overall the kicker is that this is a nasdaq quality company trading on the OTC at a 3.7 million dollar market capitalization (at the time of writing). Very interested to see how the market reacts to the news over the upcoming weeks/months.

Also would like to hear everyone else’s opinion on this stock, I will check the comment section for everyone else’s thoughts. Thank you for reading if you got this far.